CN101115498A - 用于免疫调节的HIV-1 gp41融合肽 - Google Patents

用于免疫调节的HIV-1 gp41融合肽 Download PDF

Info

Publication number
CN101115498A
CN101115498A CNA2006800022095A CN200680002209A CN101115498A CN 101115498 A CN101115498 A CN 101115498A CN A2006800022095 A CNA2006800022095 A CN A2006800022095A CN 200680002209 A CN200680002209 A CN 200680002209A CN 101115498 A CN101115498 A CN 101115498A
Authority
CN
China
Prior art keywords
amino acid
peptide
seq
cell
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800022095A
Other languages
English (en)
Chinese (zh)
Inventor
耶切尔·沙伊
伊润·R·科恩
弗朗西斯科·J·昆塔纳
多伦·格柏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN101115498A publication Critical patent/CN101115498A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800022095A 2005-01-24 2006-01-24 用于免疫调节的HIV-1 gp41融合肽 Pending CN101115498A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64560505P 2005-01-24 2005-01-24
US60/645,605 2005-01-24

Publications (1)

Publication Number Publication Date
CN101115498A true CN101115498A (zh) 2008-01-30

Family

ID=36692632

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800022095A Pending CN101115498A (zh) 2005-01-24 2006-01-24 用于免疫调节的HIV-1 gp41融合肽

Country Status (7)

Country Link
US (1) US20090270312A1 (enExample)
EP (1) EP1843777A2 (enExample)
JP (1) JP2008528480A (enExample)
CN (1) CN101115498A (enExample)
AU (1) AU2006207181A1 (enExample)
CA (1) CA2595414A1 (enExample)
WO (1) WO2006077601A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104427991A (zh) * 2012-06-27 2015-03-18 耶达研究与发展有限公司 用于治疗t细胞介导的病理的来源于hiv gp41 的肽

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138276B2 (en) 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
US8986712B2 (en) 2009-11-29 2015-03-24 Yeda Research And Development Co., Ltd. Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation
EP2717895A1 (en) * 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
KR20170080579A (ko) 2014-10-01 2017-07-10 플랜트 헬스 케어, 인코포레이티드 파괴된 과민성 반응 박스를 갖는 유발제 펩티드 및 그의 용도
JP2017530197A (ja) 2014-10-01 2017-10-12 プラント ヘルス ケア インコーポレイテッド 過敏感反応エリシターペプチド及びその使用
WO2017176588A1 (en) 2016-04-06 2017-10-12 Plant Health Care, Inc. Beneficial microbes for delivery of effector peptides or proteins and use thereof
PL3439682T3 (pl) 2016-04-06 2025-12-01 Plant Health Care, Inc. Peptydy pochodzące od czynnika wywołującego odpowiedź nadwrażliwości i ich stosowanie
WO2018037416A1 (en) * 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
EP4070815A1 (en) * 2016-10-03 2022-10-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use
WO2020085827A1 (ko) * 2018-10-24 2020-04-30 주식회사 툴젠 조작된 면역 세포

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230887A (en) * 1990-07-11 1993-07-27 Immune Network Research Ltd. Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction
US5444044A (en) * 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
US7314864B1 (en) * 1999-09-17 2008-01-01 Keio University Humanin, a polypeptide suppressing neuronal death
DE19957838C2 (de) * 1999-11-25 2002-11-21 Pette Heinrich Inst Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden
WO2005034842A2 (en) * 2003-05-19 2005-04-21 Progenics Pharmaceuticals, Inc. Peptides useful as hiv fusion inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104427991A (zh) * 2012-06-27 2015-03-18 耶达研究与发展有限公司 用于治疗t细胞介导的病理的来源于hiv gp41 的肽

Also Published As

Publication number Publication date
WO2006077601A3 (en) 2006-11-23
JP2008528480A (ja) 2008-07-31
WO2006077601A2 (en) 2006-07-27
CA2595414A1 (en) 2006-07-27
AU2006207181A1 (en) 2006-07-27
US20090270312A1 (en) 2009-10-29
EP1843777A2 (en) 2007-10-17

Similar Documents

Publication Publication Date Title
JP3802049B2 (ja) Ｈｉｖに対する中和性抗体および細胞障害性ｔリンパ球を誘発する複合合成ペプチド構築物
JP4216473B2 (ja) Ｈｉｖ感染および免疫疾患の予防および治療のペプチド組成物
TWI341844B (en) Hiv fusion inhibitor peptides with improved biological properties
RU2761653C2 (ru) Пептиды и способы для лечения диабета
SK12402001A3 (sk) Peptidy HIV, antigény, zloženie vakcín, súprava na imunologickú skúšku a spôsob detekcie protilátok vyvolaných HIV
JPH06340698A (ja) Ｈｉｖ−１ のインヒビターとしての合成ポリペプチド
AU632683B2 (en) Peptides stimulating cytotoxic t cells immune to hiv rt
KR20010085326A (ko) 바이러스 질환의 예방과 치료
US20090270312A1 (en) Hiv-i gp41 fusion peptides for immunomodulaltion
WO2016184963A1 (en) Treatment of hiv-infected individuals
US7374875B2 (en) Peptides having affinity for the gp120 viral protein and use thereof
US20150175666A1 (en) Peptides derived from hiv gp41 for treating t-cell mediated pathologies
WO2016184962A1 (en) Treatment of hiv-infected individuals
US20020076693A1 (en) Novel cell surface receptor for HIV retroviruses, therapeutic and diagnostic uses
KR100815888B1 (ko) Ｈｉｖ 보조 단백질을 암호화하는 ｄｎａ 백신
WO1991018454A1 (en) Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection
JP2010511706A (ja) Ｈｉｖ−１感染症のためのペプチド及び治療法
Rees et al. The effect of lipoylation on CD4 T-cell recognition of the 19,000 MW Mycobacterium tuberculosis antigen
AU2011269729A1 (en) Constrained immunogenic compositions and uses therefor
Lu et al. V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells
Oostendorp et al. Synthetic hexapeptides derived from the transmembrane envelope proteins of retroviruses suppress N-formylpeptide–induced monocyte polarization
FR2850384A1 (fr) Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications
US20090214583A1 (en) Epitope-enhancement of a human cd4 hiv epitope
CA2489050A1 (en) Gp41 peptides and methods based-thereon for inhibiting hiv fusion to target cells
Misumi et al. Tetragalloyl Lysine Dendrimer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080130